Here’s why I’d invest £1,000 in these two FTSE 100 stocks in a Stocks and Shares ISA today

These two FTSE 100 (INDEXFTSE:UKX) shares could offer impressive long-term returns in my opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The continued fall in the FTSE 100’s price level due to coronavirus fears could cause many investors to adopt a cautious attitude. After all, the stock market could decline further in the near term, which may make less risky assets such as cash and bonds appear to be more attractive.

However, the FTSE 100 contains a number of companies that offer defensive qualities. As such, they could offer superior performances relative to their index peers. Here are two such stocks that could deliver impressive total returns in the long run, as well as relatively low risks in the short term.

AstraZeneca

The AstraZeneca (LSE: AZN) share price has held up relatively well in recent weeks compared to the wider FTSE 100. Investors continue to be buoyed by the company’s improving financial performance over the past couple of years, with the business delivering bottom-line growth following a long period of decline.

Looking ahead, further earnings growth is forecast by the market. AstraZeneca is expected to post a rise in its bottom line of 25% next year, which could catalyse investor sentiment. It may also lead to a rising dividend, which may increase the income appeal of the stock while it has a dividend yield of 2.8% following its recent share price rise.

In addition, the pharmaceutical company’s financial performance may be less negatively impacted by market uncertainty. With investor sentiment having weakened in recent months as the threat of a slowdown in the world economy’s growth rate has increased due to the coronavirus, AstraZeneca’s defensive characteristics may increase its popularity among risk-averse investors.

As such, now could be the right time to buy the stock as it delivers improving financial performance despite a weakening global economic outlook.

Severn Trent

Another FTSE 100 company that appears to offer defensive characteristics is Severn Trent (LSE: SVT). The utility company’s outlook has improved over the past couple of months since the possibility of the sector being nationalised has declined considerably following the general election.

This could make investors more upbeat about the prospects for utility companies – especially since they have a solid track record of dividend growth and their business models are relatively immune to the prospects for the wider economy. Their increasing popularity among investors could catalyse their share prices over the medium term.

Since Severn Trent has a dividend yield of 3.8%, it seems to offer fair value for money. Certainly, there are risks ahead for the sector, such as from regulatory change. But with the UK economy facing an uncertain period due to Brexit, and the world economy’s growth rate having been negatively impacted by the coronavirus, the risk/reward ratio offered by Severn Trent could mean that now is the right time to buy a slice of it and hold it for the long run.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »